Group purchasing organizations and purchasing groups, affiliations, and coalitions
We realize that in healthcare, you can’t go it alone. It takes partners and associates coming together in collaboration to achieve efficient, cost-effective care for patients. We also understand the financial and operational pressures faced by today’s hospitals and healthcare systems, because we are a hospital too. Group purchasing organizations (GPOs) and purchasing groups (PGs) help hospitals by shouldering the burden of negotiating the best member pricing and benefits with quality suppliers. At Mayo Clinic Laboratories, we welcome the opportunity to serve members by establishing relationships with their GPOs and PGs to provide member access to our broad esoteric testing menu and services.
Building laboratory value
The financial pressure on hospitals continues. To help, we can support hospital laboratories by evaluating current utilization, capacity, and processes to help reduce waste, find efficiencies, and maximize capabilities for optimal financial performance.
We also offer support in building and expanding laboratory outreach programs. Our experienced, industry-leading outreach consultants offer unparalleled insights and experience to help hospital-based laboratories evolve from cost-centers to revenue generators. Learn more about how we can support laboratories’ optimization and revenue-generation goals.
Driving efficiency through consolidation
Most hospital laboratories find themselves sending tests to an increasing number of commercial and specialty reference laboratories. Managing the complexities of these various relationships increases operational burden, staff workload, and inconsistencies in testing methods and interpretation of results.
Hospitals and health systems can optimize their laboratory testing referrals by leveraging our extensive test menu, which includes advanced diagnostics, cutting-edge technology, and clinically relevant new tests across our full spectrum of medical subspecialties.
“The type of service we provide is really tailored to the needs of the hospital or to the healthcare system. And their patients are no different than the patients that walk through our doors.”
William Morice, M.D., Ph.D., CEO and President of Mayo Clinic Laboratories
Sharing knowledge and empowering staff
We support care teams by providing insights and education as they strive to solve the most complex medical challenges. Our education offerings range from conferences to on-demand programs to webinars — many of which offer CME credit. View our extensive educational offerings.
In addition, hospital and laboratory staff have direct access to Mayo Clinic physicians and scientists, who can help with optimizing test orders and interpreting results. Mayo Clinic Laboratories provides each client with a dedicated team of account, clinical, and laboratory technical professionals.
Prioritizing patient care
With guidance from our practicing physicians, we continuously develop testing algorithms, invest in research, and develop new tests so that patients have access to the best testing available. As a hospital-based reference laboratory, our focus is helping clients prevent overutilization of laboratory testing, drive efficiency through consolidation of send-out testing, and generate hospital revenue by establishing and growing lab outreach programs. And, we provide benefits only available through a connection with a world-class medical institution: access to our Mayo Clinic physicians and consultants, educational offerings, and the most cutting-edge, clinically-based testing available in the market.
News and updates
The latest
Join us Sept. 23–24, 2026, in Rochester, Minnesota, for our annual outreach conference. This year’s event, Leveraging the Laboratory: Bold Thinking. Big Impact., focuses on how innovative approaches and strategic decision-making can drive meaningful results for health system laboratory outreach programs.
This week's research roundup feature: Renal fibrosis is now recognized as a main determinant of renal pathology to include chronic kidney disease. Deposition of pathological matrix in the walls of glomerular capillaries, the interstitial space, and around arterioles predicts and contributes to the functional demise of the nephron and its surrounding vasculature.
Patients want to use a laboratory that is easy to work with, and there are different definitions of “easy.” Ultimately, health systems want to have the patients they serve use their health system laboratories. If patients are choosing to go elsewhere, the laboratory should review and respond to several key patient experience factors.
In this month’s “Hot Topic,” Anne Tebo, Ph.D., discusses recent updates in the testing for anti-SS-A/Ro antibodies in systemic autoimmune rheumatic diseases.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Robert Fazzio, M.D., Ph.D., assistant professor of radiology and chair of the Division of Breast Imaging at Mayo Clinic in Rochester, Minnesota.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss how artificial intelligence (AI) has become a disruptive technology in the field of laboratory medicine, and how it can add value to patient care.
Eight years ago, Tamara Staley joined Mayo Clinic Laboratories’ Cardiovascular Sales team selling CV diagnostic testing to community hospitals. Now, she leads sales for Hematology and Oncology’s Central Region. Tamara is proud to help connect physicians and patients to a wide variety of oncology solid tumor testing that includes breast cancer testing.
This week's research roundup feature: Given the prevalence of dementia and the development of pathology-specific disease modifying therapies, high-value biomarker strategies to inform medical decision making are critical. In-vivo tau positron emission tomography (PET) is an ideal target as a biomarker for Alzheimer's disease diagnosis and treatment outcome measure.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current focus areas found across the diagnostics industry and what transformative technologies are being explored around the world.
In a recent discovery by Mayo Clinic Laboratories, a novel hemoglobinopathy category was identified and termed epsilon gamma thalassemia. The first instance of the disorder was found in 2017 when an obstetric patient underwent a routine screening for blood-related illnesses such as sickle cell disease and thalassemia. Upon completion of additional tests, doctors found an abnormality they had never seen before.
Mayo Clinic launched an automated system called RENEW — reanalysis of negative whole-exome/genome data — in 2022 that tracks newly published discoveries of disease-causing genetic variants. Every three months, the system automatically uploads these new scientific findings from around the world, which are then compared to the Mayo Clinic Center for Individualized Medicine’s database of unsolved patient sequencing results. This comparison helps to identify potentially significant developments that could lead to a new diagnosis for a patient with a rare genetic disorder.
This week's research roundup feature: Membranous nephropathy (MN) is a pattern of injury caused by autoantibodies binding to specific target antigens, with accumulation of immune complexes along the subepithelial region of glomerular basement membranes.
In August of 2021, 28-year-old Mike Knudson, a Twin Cities resident known for his vibrant and active lifestyle, set out on what he anticipated to be an adventurous hiking vacation to the picturesque Glacier National Park in Montana. Little did he know that this journey in nature would be the start of an unexpected life path.